Su1225 - Helicobacter Pylori Antibiotic Resistance Patterns Among Non-Us Born and Us-Born Patients from an Ethnically Diverse Population Who Failed First-Line Therapy

Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis

“…In that report, the clarithromycin resistance rate was 60% (39/65), metronidazole 41.5% (27/65), and levofloxacin 69.2% (45/65). Lin et al (29) evaluated the resistance rates among patients who had failed at least 1 previous therapy attempt to be 81.8% (45/55) for clarithromycin, 7.4% (4/54) for amoxicillin, 81.8% (45/55) for metronidazole, 2.9% (1/35) for tetracycline, and 70.9% (39/55) for levofloxacin. Fradkov and Tan (27,28) both reported resistance rates in patients who had failed at least 2 therapies.…”

“…We included studies published in English containing information on H. pylori resistance rates to clarithromycin (12–29), amoxicillin (13,15,17,20–25,27–29), metronidazole (13,15,17,20–30), tetracycline (13,15,17,20,21,23–25,27–30), rifabutin (23–25), levofloxacin (13,17,20,21,23–26,29), or a combination thereof. We excluded studies if the population was not from the United States, was not based on defined patient groups, reported only rates without number of isolates, evaluated only a pediatric population (age <18 years), or contained data previously reported in other publications.…”

“…We included studies published in English containing information on H. pylori resistance rates to clarithromycin (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29), amoxicillin (13,15,17,(20)(21)(22)(23)(24)(25)(27)(28)(29), metronidazole (13,15,17,(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30), tetracycline (13,15,17,20,21,(23)(24)…”